+

WO2009143018A3 - Composés et procédés de modulation des kinases, et indications associées - Google Patents

Composés et procédés de modulation des kinases, et indications associées Download PDF

Info

Publication number
WO2009143018A3
WO2009143018A3 PCT/US2009/044151 US2009044151W WO2009143018A3 WO 2009143018 A3 WO2009143018 A3 WO 2009143018A3 US 2009044151 W US2009044151 W US 2009044151W WO 2009143018 A3 WO2009143018 A3 WO 2009143018A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidines
pyrrolo
kit kinase
kinase modulators
scheloris
Prior art date
Application number
PCT/US2009/044151
Other languages
English (en)
Other versions
WO2009143018A2 (fr
Inventor
Prabha N. Ibrahim
Ryan Bremer
Jiazhong Zhang
Marika Nespi
Hanna Cho
Original Assignee
Plexxikon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon, Inc. filed Critical Plexxikon, Inc.
Publication of WO2009143018A2 publication Critical patent/WO2009143018A2/fr
Publication of WO2009143018A3 publication Critical patent/WO2009143018A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)

Abstract

La présente invention concerne des composés et leurs sels, leurs formulations, leurs conjugués, leurs dérivés, leurs formes et leurs utilisations. Dans certains aspects et modes de réalisation, les composés décrits ou leurs sels, leurs formulations, leurs conjugués, leurs dérivés, leurs formes sont actifs sur au moins l’une de la protéine kinase Fms ou de la protéine kinase Kit. La présente invention concerne également des procédés d’utilisation de ceux-ci pour le traitement de maladies et de conditions, comprenant des maladies et des conditions associées à l’activité des protéines kinases Fms et/ou des protéines kinases Kit, comprenant la polyarthrite rhumatoïde, l’arthrose, l'ostéoporose, l’ostéolyse péri-prothétique, une sclérose systémique, des troubles de démyélinisation, la sclérose en plaques, le syndrome Charcot Marie Tooth, la sclérose latérale amyotrophique, la maladie d'Alzheimer, la maladie de Parkinson, une rectocolite hémorragique, la maladie de Crohn, le purpura thrombocytopénique immun, la myélopréparation pour une transplantation autologue, le rejet de transplantation, une néphrite, une néphropathie, le diabète de type I, une douleur aiguë, une douleur inflammatoire, une douleur neuropathique, le cancer du sein, le cancer de la prostate, le cancer du pancréas, le cancer du poumon, le cancer des ovaires, des gliomes, des glioblastomes, une neurofibromatose, des métastases osseuses ostéolytiques, et des tumeurs à cellules géantes.
PCT/US2009/044151 2008-05-19 2009-05-15 Composés et procédés de modulation des kinases, et indications associées WO2009143018A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5445108P 2008-05-19 2008-05-19
US61/054,451 2008-05-19

Publications (2)

Publication Number Publication Date
WO2009143018A2 WO2009143018A2 (fr) 2009-11-26
WO2009143018A3 true WO2009143018A3 (fr) 2010-04-15

Family

ID=40999847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044151 WO2009143018A2 (fr) 2008-05-19 2009-05-15 Composés et procédés de modulation des kinases, et indications associées

Country Status (4)

Country Link
US (3) US8158636B2 (fr)
AR (1) AR071839A1 (fr)
TW (1) TW200948816A (fr)
WO (1) WO2009143018A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR20100122505A (ko) * 2008-02-29 2010-11-22 어레이 바이오파마 인크. Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
ES2400202T3 (es) * 2008-02-29 2013-04-08 Array Biopharma, Inc. Inhibidores de RAF de pirazol[3,4-B]piridina
JP2011513329A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2010014784A2 (fr) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
CN102224153B (zh) 2008-09-22 2014-04-30 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SG10201407718WA (en) 2009-11-18 2015-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
BR112012015745A2 (pt) 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
CN102892768A (zh) * 2009-12-30 2013-01-23 艾科尔公司 被取代的吡咯并氨基嘧啶化合物
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9073918B2 (en) 2010-05-20 2015-07-07 Takeda Pharmaceutical Company Limited Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
DK2576548T3 (en) * 2010-05-26 2015-09-28 Adverio Pharma Gmbh USE OF sGC stimulators, sGC activators alone and in combination with PDE5 inhibitors for treating systemic sclerosis (SSc)
TR201816421T4 (tr) 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
PH12013502020A1 (en) * 2011-04-05 2018-04-11 Pfizer Ltd Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
BR112013029163A2 (pt) 2011-05-17 2017-01-31 Plexxikon Inc modulação quinase e indicações dos mesmos
CA2841111A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Nouveaux derives de pyrrolopyrimidine
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
WO2014039714A2 (fr) 2012-09-06 2014-03-13 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
EP2903986A1 (fr) 2012-10-04 2015-08-12 Pfizer Limited Inhibiteurs de kinases apparentés à la tropomyosine
EP2903989A1 (fr) 2012-10-04 2015-08-12 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[2,3-d]pyrimidine
EP2912036A1 (fr) 2012-10-04 2015-09-02 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
ME03000B (fr) 2012-12-21 2018-10-20 Plexxikon Inc Composés et procédés pour la modulation de kinase, et indications associées
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2014145051A1 (fr) 2013-03-15 2014-09-18 Jiazhong Zhang Composés hétérocycliques et leurs utilisations
EP2983674A4 (fr) 2013-04-08 2017-05-10 Dennis M. Brown Bénéfice thérapeutique de composés chimiques administrés de façon sous-optimale
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US20160082015A1 (en) * 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
US9873700B2 (en) 2013-05-30 2018-01-23 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
JP2016540811A (ja) 2013-12-20 2016-12-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
EP3099694B1 (fr) 2014-01-29 2019-01-16 GlaxoSmithKline Intellectual Property Development Limited Composés
CN105940004B (zh) 2014-01-29 2018-02-02 葛兰素史密斯克莱知识产权发展有限公司 化合物
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2015159175A1 (fr) 2014-04-15 2015-10-22 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine contenant à la fois un 1h-pyrazole et un fragment pyrimidine
EP3140298A1 (fr) 2014-05-07 2017-03-15 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
JP6832846B2 (ja) 2014-09-15 2021-02-24 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環化合物およびその用途
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
JP6797801B2 (ja) 2014-12-22 2020-12-09 ファイヴ プライム セラピューティクス インク Ｐｖｎｓを治療するための抗ｃｓｆ１ｒ抗体
CA2973597A1 (fr) 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Inhibiteurs d'itk heterocycliques pour traiter l'inflammation et le cancer
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2730506C2 (ru) 2015-05-06 2020-08-24 Плексксикон Инк. Твердые формы соединения, модулирующего киназы
BR112017023540B1 (pt) 2015-05-06 2023-04-04 Plexxikon, Inc. Processos de preparação de derivados de 1h-pirrolo[2,3-b]piridina que modulam quinases
CA2986735A1 (fr) 2015-05-22 2016-12-01 Plexxikon Inc. Formes solides d'un compose de modulation des kinases
BR112017025045A2 (pt) 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
EP3303303A1 (fr) * 2015-05-29 2018-04-11 Pfizer Inc Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de l'enzyme vanine-1
SI3319959T1 (sl) 2015-07-06 2022-02-28 Alkermes, Inc. Hetero-halo inhibitorji histonske deacetilaze
EP3319968A1 (fr) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
IL276292B2 (en) 2015-07-20 2024-02-01 Genzyme Corp CSF–1R receptor antagonists
WO2017019804A2 (fr) 2015-07-28 2017-02-02 Plexxikon Inc. Composés et procédés de modulation des kinases, et indications associées
PE20181093A1 (es) 2015-09-21 2018-07-09 Plexxikon Inc Compuestos heterociclicos y usos de los mismos
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
CN108368110A (zh) 2015-12-07 2018-08-03 普莱希科公司 用于激酶调节的化合物和方法以及其适应症
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HRP20241282T1 (hr) 2016-04-04 2024-12-06 Loxo Oncology, Inc. Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid
SI3439663T1 (sl) 2016-04-04 2024-11-29 Loxo Oncology, Inc. Metode zdravljenja pediatričnih rakov
RS61463B1 (sr) 2016-05-18 2021-03-31 Loxo Oncology Inc Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il) -3-hidroksipirolidin-1-karboksamida
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA2968836A1 (fr) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
WO2018039310A1 (fr) 2016-08-24 2018-03-01 Arqule, Inc. Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
EP3568135B1 (fr) 2017-01-11 2021-04-07 Alkermes, Inc. Inhibiteurs bicycliques d'histone désacétylase
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
EP3571203B1 (fr) 2017-01-18 2023-06-07 Array BioPharma Inc. Composés de pyrazolo[1,5-a]pyrazine substitués utilisés en tant qu'inhibiteurs de la kinase ret
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3601281B1 (fr) 2017-03-20 2021-09-29 Plexxikon Inc. Formes cristallines de l'acide 4-(1-(1,1-di(pyridin-2-yl)éthyl)-6-(3,5-diméthylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoïque en tant que inhibiteur de bromodomaine
EP3600309B1 (fr) 2017-03-28 2022-06-22 Gilead Sciences, Inc. Combinaisons thérapeutiques pour le traitement de maladies du foie
WO2018226846A1 (fr) 2017-06-07 2018-12-13 Plexxikon Inc. Composés et procédés de modulation de kinase
JP7170030B2 (ja) 2017-07-25 2022-11-11 プレキシコン インコーポレーテッド キナーゼを調節する化合物の製剤
KR20200037286A (ko) 2017-08-07 2020-04-08 로딘 테라퓨틱스, 인크. 히스톤 데아세틸라제의 비사이클릭 억제제
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3694855A1 (fr) 2017-10-13 2020-08-19 Plexxikon Inc. Formes solides d'un composé pour la modulation de kinases
CA3080197C (fr) 2017-10-27 2023-12-19 Plexxikon Inc. Formulation d'un compose modulant les kinases
WO2019143994A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrazolyl[4,3-c]pyridine substitués utilisés en tant qu'inhibiteurs de la kinase ret
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CA3094336A1 (fr) 2018-03-20 2019-09-26 Plexxikon Inc. Composes et procedes de modulation d'ido et de tdo, et indications pour ceux-ci
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
US20210308171A1 (en) * 2018-08-07 2021-10-07 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof
CN113164419A (zh) 2018-09-07 2021-07-23 皮克医疗公司 Eif4e抑制剂和其用途
WO2020055672A1 (fr) 2018-09-10 2020-03-19 Array Biopharma Inc. Composés hétérocycliques condensés comme inhibiteurs de kinases ret
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
PL3911647T3 (pl) 2019-01-15 2024-05-20 Gilead Sciences, Inc. Związek izoksazolowy jako agonista fxr oraz zawierające go kompozycje farmaceutyczne
AU2020225225B2 (en) 2019-02-19 2022-12-22 Gilead Sciences, Inc. Solid forms of FXR agonists
TW202104221A (zh) 2019-04-09 2021-02-01 美商普雷辛肯公司 用於ep300或cbp調節及其適應症之化合物及方法
WO2021029450A1 (fr) * 2019-08-09 2021-02-18 한국화학연구원 Nouveau dérivé de pyrimidine sulfonamide et composition pharmaceutique pour prévenir ou traiter le cancer le comprenant en tant que principe actif
WO2021113492A1 (fr) 2019-12-06 2021-06-10 Schrödinger, Inc. Composés cycliques et leurs procédés d'utilisation
US20240018157A1 (en) 2019-12-27 2024-01-18 Schrödinger, Inc. Cyclic compounds and methods of using same
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use
WO2021144360A1 (fr) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Inhibiteurs csf-1r à petites molécules en utilisations thérapeutiques et cosmétiques
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
US11807626B2 (en) 2020-04-23 2023-11-07 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
CN111675644B (zh) * 2020-06-08 2022-12-23 南京医科大学 一种吲哚类二芳基甲烷化合物及其制备方法和应用
US11628176B2 (en) 2020-08-21 2023-04-18 Opna Bio SA Combinational drug therapies
JP2023541047A (ja) 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
EP4284804A1 (fr) 2021-01-26 2023-12-06 Schrödinger, Inc. Composés tricycliques utiles dans le traitement du cancer, des troubles auto-immuns et des troubles inflammatoires
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
WO2025059027A1 (fr) 2023-09-11 2025-03-20 Schrödinger, Inc. Dérivés de cyclopenta[e]pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de malt1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056830A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Derives de pyrrolopyrimidine
WO2005116035A1 (fr) * 2004-05-27 2005-12-08 Pfizer Products Inc. Derives pyrrolopyrimidiniques convenant au traitement du cancer
WO2007013896A2 (fr) * 2005-05-17 2007-02-01 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171062A1 (en) 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
MXPA05002444A (es) * 2002-09-06 2005-09-30 Insert Therapeutics Inc Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
AU2003272548A1 (en) 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
US20050048573A1 (en) 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
WO2004078923A2 (fr) 2003-02-28 2004-09-16 Plexxikon, Inc. Structure cristalline de pyk2 et ses utilisations
US20050079548A1 (en) 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
US7202266B2 (en) 2003-07-17 2007-04-10 Plexxikon, Inc. PPAR active compounds
WO2005028624A2 (fr) 2003-09-15 2005-03-31 Plexxikon, Inc. Echafaudages moleculaires pour le developpement de ligands des proteines kinases
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
SI1696920T1 (sl) 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
US7517970B2 (en) 2003-12-19 2009-04-14 Plexxikon, Inc. Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same
WO2006078287A2 (fr) 2004-05-06 2006-07-27 Plexxikon, Inc. Inhibiteurs de pde4b
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1755597A2 (fr) 2004-06-17 2007-02-28 Plexxikon, Inc. Composes modulant l'activite de c-kit
WO2006026754A2 (fr) 2004-09-03 2006-03-09 Plexxikon, Inc. Inhibiteurs de la phosphodiesterase 4b (pde4b)
WO2006060535A2 (fr) 2004-11-30 2006-06-08 Plexxikon, Inc. Composes actifs ppar
EP1819673A2 (fr) 2004-11-30 2007-08-22 Plexxikon, Inc. Derivés indole utiles comme des composés actifs sur les ppar
US20060160135A1 (en) 2004-12-08 2006-07-20 Weiru Wang SF-1 and LRH-1 modulator development
CA2613015C (fr) 2005-06-22 2012-04-03 Plexxikon, Inc. Derives de pyrrolo [2, 3-b] pyridine utilises comme inhibiteurs de proteines kinases
EP1943245A2 (fr) 2005-09-07 2008-07-16 Plexxikon, Inc. Dérivés d'indole disubstitué en 1,3 pour utilisation comme composés agissant sur les ppar
AU2006287528A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as PPAR active compounds
TW200800872A (en) 2005-09-07 2008-01-01 Plexxikon Inc PPAR active compounds
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
EP2094701A2 (fr) 2006-12-21 2009-09-02 Plexxikon, Inc. Composés et procédés pour la modulation de kinases et indications pour celle-ci
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
CN101668737A (zh) 2007-03-08 2010-03-10 普莱希科公司 Ppar活性化合物
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009152087A1 (fr) 2008-06-10 2009-12-17 Plexxikon, Inc. Composés hétéroaryles bicycliques et procédés destinés à la modulation de kinases, et des indications pour celle-ci
CA2727389A1 (fr) 2008-06-10 2009-12-17 Prabha N. Ibrahim Derives 5h-pyrrolo-[2,3-b]-pyrazine destines a la modulation de kinases, et des indications pour ceux-ci
CN102421776A (zh) 2009-03-11 2012-04-18 普莱希科公司 抑制Raf激酶的吡咯并[2，3-b]吡啶衍生物
KR20110130463A (ko) 2009-03-11 2011-12-05 플렉시콘, 인코퍼레이티드 Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체
WO2010111527A1 (fr) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
CA2761009A1 (fr) 2009-05-04 2010-11-11 Plexxikon, Inc. Composes et procedes pour inhiber la renine, et indications associees
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2011057022A1 (fr) 2009-11-06 2011-05-12 Plexxikon, Inc. Composés et méthodes de modulation des kinases et leurs indications d'emploi
SG10201407718WA (en) 2009-11-18 2015-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
BR112012015745A2 (pt) 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8642606B2 (en) 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
TR201816421T4 (tr) 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
BR112013029163A2 (pt) 2011-05-17 2017-01-31 Plexxikon Inc modulação quinase e indicações dos mesmos
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014039714A2 (fr) 2012-09-06 2014-03-13 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
ME03000B (fr) 2012-12-21 2018-10-20 Plexxikon Inc Composés et procédés pour la modulation de kinase, et indications associées
WO2014145051A1 (fr) 2013-03-15 2014-09-18 Jiazhong Zhang Composés hétérocycliques et leurs utilisations
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
US9873700B2 (en) 2013-05-30 2018-01-23 Plexxikon Inc. Compounds for kinase modulation, and indications therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056830A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Derives de pyrrolopyrimidine
WO2005116035A1 (fr) * 2004-05-27 2005-12-08 Pfizer Products Inc. Derives pyrrolopyrimidiniques convenant au traitement du cancer
WO2007013896A2 (fr) * 2005-05-17 2007-02-01 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE INTERNET USPTO; 1 September 2009 (2009-09-01), "http://www.uspto.gov", XP007909620 *
DUMAS J: "Protein kinase inhibitors: Emerging pharmacophores 1997 - 2000", EXPERT OPINION ON THERAPEUTIC PATENTS 2001 GB, vol. 11, no. 3, 2001, pages 405 - 429, XP002543698, ISSN: 1354-3776 *
PRIEN OLAF: "Target-family-oriented focused libraries for kinases--conceptual design aspects and commercial availability.", CHEMBIOCHEM : A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY MAR 2005, vol. 6, no. 3, March 2005 (2005-03-01), pages 500 - 505, XP002543697, ISSN: 1439-4227 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Also Published As

Publication number Publication date
AR071839A1 (es) 2010-07-21
US8912204B2 (en) 2014-12-16
US8158636B2 (en) 2012-04-17
TW200948816A (en) 2009-12-01
US20150166547A1 (en) 2015-06-18
WO2009143018A2 (fr) 2009-11-26
US9260437B2 (en) 2016-02-16
US20090286782A1 (en) 2009-11-19
US20120165329A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2009143018A3 (fr) Composés et procédés de modulation des kinases, et indications associées
BRPI0619817B8 (pt) composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
MY152948A (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
TN2013000419A1 (en) Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
CL2008001709A1 (es) Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CL2012002937A1 (es) Compuestos derivados de 1h-pirrolo[2,3-b]piridina o 7h-pirrolo[2,3-d]pirimidina sustituidos, moduladores de quinasa; composición farmacéutica; kit farmacéutico; método de preparación;y su uso para tratar artritis reumatoide, osteoporosis, alzheimer, cancer pancreatico, cancer de protata y mieloma multiple.
EP4406616A3 (fr) Pyrazolo(1,5-a)pyrimidines substituees et leur utilisation dans le traitement de troubles medicaux
WO2010077680A3 (fr) Compositions d'inhibiteurs de tyrosine kinase de récepteur protéique
UA105813C2 (uk) Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
WO2011051342A8 (fr) Dérivés d'imidazo[1,2-b]pyridazine et leur utilisation comme inhibiteurs de pde10
EA200701500A1 (ru) СПОСОБЫ ПОЛУЧЕНИЯ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ ЭФИРОВ
WO2006069080A3 (fr) Pyrrolo[2,3-b]pyridin-4-yl-amines et pyrrolo[2m3-b]pyrimidin-4-yl-amines utilisees en tant qu'inhibiteurs des janus kinases
WO2008134761A3 (fr) Modification des groupes de ciblage biologiques pour le traitement du cancer
IL212814B (en) Pyrimidines are converted to treat diseases such as cancer
WO2010042925A3 (fr) Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d'autres maladies
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
PL2024368T3 (pl) Pochodne 6,7,8,9-tetrahydro-5H-pirymido[4,5-d]azepin-4-ylo]-aminy jako modulatory TRPV1 do leczenia bólu
WO2014093230A3 (fr) Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk
WO2008033745A3 (fr) Pyrimidines bicycliques fusionnées servant d'inhibiteurs de ptk contenant un groupe de liaison au zinc
EP2419425A4 (fr) Pyrimidines substituées par imidazole utiles dans le traitement de troubles liés à la glycogène synthase kinase 3, tels que la maladie d'alzheimer
MX2010001581A (es) Hidantoinas substituidas.
TW200602348A (en) Thieno[3, 2-b]pyridine-6-carbonitriles as protein kinase inhibitors
WO2009034547A3 (fr) Nouveaux dérivés 4-substitués de la pyrazolo[3,4-d]pyrimidine et de la pyrrolo[2,3-d]pyrimidine et leurs utilisations
EP4327884A3 (fr) Dérivés de 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazépine et composés similaires en tant que modulateurs de kinase lrrk2, nuak1 et/ou tyk2 pour le traitement de p.e. maladies auto-immunes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751247

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09751247

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载